anti-ARF, p14 antibody product blog
Tags: Antibody; Polyclonal Antibody; ARF, p14; anti-ARF, p14 antibody;
The ARF, p14 n/a (Catalog #MBS623649) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The ARF, p14 reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s ARF, p14 can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA). Researchers should empirically determine the suitability of the ARF, p14 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
The INK4a-ARF locus is comprised of two tumor suppressors, p16INK4a and p14ARF. These two proteins are encoded through differential splicing of alternative first exons. The p16INK4a (exon 1alpha) protein inhibits the cyclin D-dependent kinases (CDK) that control the phosphorylation of the Rb protein and cell proliferation. The p14ARF gene product complexes with the MDM2 protein within the nucleus, thus modulating the activity of the p53 protein. P14ARF is a potent tumor suppressor in the presence of wild-type p53, while mutant p53 substantially reduces growth inhibition by p14ARF. (1-3).
Immunogen: Synthetic peptide from the human sequence of p14ARF. Positive Control: BT549 cells. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing ARF, p14 are readily searchable from our website. Different antibodies against the same target such as ARF, p14 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.